At the news
? NEUTRALIMPACT 2/10 8-K filed Sep 14, 2026 at 08:00 ET
NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors and analysts on September 8, 2026. The filing is a routine Regulation FD disclosure with no new material financial data, guidance, or corporate events. The presentation content was not extractable from the provided documents, limiting analysis to the filing's procedural nature.
- NRX Pharmaceuticals filed an 8-K on September 14, 2026, regarding Item 7.01 Regulation FD Disclosure.
- The filing furnishes an investor presentation (Exhibit 99.1) used in meetings on September 8, 2026.
- No financial results, guidance, or material corporate events were disclosed in the 8-K body.
- The investor presentation content was not available for analysis.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access